Bridging Preclinical Models & Clinical Success: Leveraging PDOs & RWD to Advance ADC Development
- Applying RWD to identify novel therapeutic targets and provide insights into ADC development with responder populations
- Examining how patient-derived organoids can enhance biomarker validation and help guide therapeutic decisions
- Highlighting a “lab-in-theloop” approach to incorporate screening panels of PDOs, optimized for ADC evaluation, and RWD to enhance biomarker validation and guide pipeline prioritization